In SLE, persistent immune activation and the release of pro-inflammatory cytokines, such as interferon-alpha (IFN-α) and interleukin-6 (IL-6), contribute to endothelial injury and promote a pro-atherogenic environment [5]. Here, IL6 is linked to systemic lupus erythematosus.